Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Cryo-Cell International's 3-Year ROIIC % for the quarter that ended in Nov. 2025 was -16.07%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Cryo-Cell International's 3-Year ROIIC % or its related term are showing as below:
FRA:ZCY's 3-Year ROIIC % is ranked worse than 73.55% of 620
companies
in the Healthcare Providers & Services industry
Industry Median: 3.47
vs FRA:ZCY: -16.07
Cryo-Cell International (FRA:ZCY) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Cryo-Cell International 3-Year ROIIC % Related Terms
Cryo-Cell International 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ZCY vs EHSI, PIII, CCM: 3-Year ROIIC % Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's 3-Year ROIIC % falls into.
Cryo-Cell International 3-Year ROIIC % Calculation
Cryo-Cell International's 3-Year ROIIC % for the quarter that ended in Nov. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 4.187 (Nov. 2025) - 3.65225 (Nov. 2022) )
/
( 54.162 (Nov. 2025) - 68.247 (Nov. 2022) )
=
0.53475
/
-14.085
=
-3.80%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Cryo-Cell International (FRA:ZCY) has a 3-Year ROIIC % of -16.07 as of Nov. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Cryo-Cell International and its competitors. According to the industry distribution chart, Cryo-Cell International ranks #456 out of 620 companies in the Healthcare Providers & Services industry, placing it in the top 73.5%.
Is Cryo-Cell International's 3-Year ROIIC % too high?
Cryo-Cell International's current 3-Year ROIIC % is -16.07. Based on the distribution chart, Cryo-Cell International ranks #456 out of 620 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Cryo-Cell International has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's 3-Year ROIIC % compare to EHSI and PIII?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #456 out of 620 companies for 3-Year ROIIC %. This places Cryo-Cell International in the lower half of its industry. The industry median 3-Year ROIIC % is 3.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.47, based on 620 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current 3-Year ROIIC % is -16.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Cryo-Cell International (FRA:ZCY) has a current 3-Year ROIIC % of -16.07. The stock's GF Value™ is €4.44, compared to a current price of €2.74 — trading 38.3% below its estimated fair value. The current 3-Year ROIIC % is -16.07. Cryo-Cell International's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Cryo-Cell International (FRA:ZCY), the current 3-Year ROIIC % is -16.07 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (FRA:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €2.74 is trading 38.3% below its estimated GF Value™ of €4.44.
Key valuation signals for FRA:ZCY:
3-Year ROIIC %: -16.07
GF Value™: €4.44 vs. price of €2.74 (38.3% below fair value)
No single metric tells the full story. See the FRA:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
57GF Score
Get the complete analysis for FRA:ZCY
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZCY has been successfully added to your 
